Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds
Randomized, Exploratory Study to Evaluate Changes to Skin Microbiome With Tape-stripped Wounds
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Fair Lawn, New Jersey, United States, 07410
- TKL Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 to 55 years of age.
- Fitzpatrick skin types I to III.
- Must be able to comprehend and follow the requirements of the study
- Avoid excessive sun exposure
- Willing to refrain from topical product use on the back for the duration of the study.
- Subjects must agree not to immerse their bandages in water for the duration of the study.
- Male and female subjects with reproductive potential who agree to practice a medically acceptable form of birth control
Exclusion Criteria:
- Excessively hairy back, acne, scars and pigmentation or nevi t
- . Pregnant or Lactating, or planning on becoming pregnant;
- . Known allergies or sensitivities to anesthetics, adhesive bandages, wound treatment products or tapes;
- . Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
- Participation in any other clinical study within 30 days of Visit 1;
- . Subjects who have a health condition and/or pre-existing or dormant dermatologic conditions or who have clinically active bacterial, fungal, or viral skin infections or those who are susceptible to cutaneous infections
- Subjects who report using prescription or OTC medication (oral or topical) that can make skin more sensitive or influence the skin (i.e. antibiotics, hormones, insulin, etc.)
- Subjects receiving topical and/or inhaled medications that may alter or compromise the bleeding/healing process
- Individuals with a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications and/or radiation
- . Subjects with a known history of keloid or hypertrophic scar formation;
- Subjects diagnosed with any blood clotting disorder;
- Hyperthyroidism or hypothyroidism or with active or recently treated (within 1 year) skin cancer, or those in poor nutritional status; 13 Subjects taking oral Vitamin A derivatives such as Accutane, isotretinon, or using retinoic acid in the past 1 year or using topical Vitamin A derivatives in the 3 weeks prior to study start;
14. Subjects with clinically infected skin lesions; 15. Subjects with cracked or excoriated skin, or other skin problems. 16. Diabetes mellitus that cannot be controlled by diet alone (i.e. requires systemic medications for control); 17. Subjects with friable skin, at the discretion of the Investigator;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ADHESIVE BANDAGE #1
bandage applied to wounded site.
|
Bandage applied daily to wounded site for 14 days
|
|
Experimental: ADHESIVE BANDAGE #2
bandage applied to wounded site.
|
Bandage applied daily to wounded site for 14 days
|
|
Experimental: ADHESIVE BANDAGE #3
bandage applied to wounded site
|
Bandage applied daily to wounded site for 14 days
|
|
Experimental: Antibacterial Bandage with 0.8% BZK
bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
|
bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
|
|
Other: Intact and No Bandage
This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
|
This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
|
|
Other: Wounded and No Bandage
This test site will be wounded and no bandage applied, serving as a positive control site.
|
This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microbial Community Richness - Baseline (Day 0)
Time Frame: Baseline (Day 0)
|
Swabs will be collected on the back at Baseline (Day 0) and analyzed to determine the total number of different bacterial taxa (microorganisms) detected in the sample.
There was no prespecified primary endpoint in the protocol.
|
Baseline (Day 0)
|
|
Microbial Community Richness - (Day 1)
Time Frame: Day 1
|
Swabs will be collected on the back at Day 1 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.
|
Day 1
|
|
Microbial Community Richness - (Day 2)
Time Frame: Day 2
|
Swabs will be collected on the back at Day 2 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.
|
Day 2
|
|
Microbial Community Richness - (Day 3)
Time Frame: Day 3
|
Swabs will be collected on the back at Day 3 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.
|
Day 3
|
|
Microbial Community Richness - (Day 4)
Time Frame: Day 4
|
Swabs will be collected on the back at Day 4 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.
|
Day 4
|
|
Microbial Community Richness - (Day 5)
Time Frame: Day 5
|
Swabs will be collected on the back at Day 5 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.
|
Day 5
|
|
Microbial Community Richness - (Day 6)
Time Frame: Day 6
|
Swabs will be collected on the back at Day 6 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.
|
Day 6
|
|
Microbial Community Richness - (Day 7)
Time Frame: Day 7
|
Swabs will be collected on the back at Day 7 and analyzed to determine the total number of different bacteria Taxa (microorganismss) detected in the sample.
|
Day 7
|
|
Microbial Community Richness - (Day 14)
Time Frame: Day 14
|
Swabs will be collected on the back at Day 14 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.
|
Day 14
|
|
Microbial Community Diversity - Baseline (Day 0)
Time Frame: Baseline (Day 0)
|
Swabs will be collected on the back at Baseline (Day 0) for analysis based on the Shannon Index.
|
Baseline (Day 0)
|
|
Microbial Community Diversity - Day 1
Time Frame: Day 1
|
Swabs will be collected on the back at Day 1 for analysis based on the Shannon Index.
|
Day 1
|
|
Microbial Community Diversity - Day 2
Time Frame: Day 2
|
Swabs will be collected on the back at Day 2 for analysis based on the Shannon Index.
|
Day 2
|
|
Microbial Community Diversity - Day 3
Time Frame: Day 3
|
Swabs will be collected on the back at Day 3 for analysis based on the Shannon Index.
|
Day 3
|
|
Microbial Community Diversity - Day 4
Time Frame: Day 4
|
Swabs will be collected on the back at Day 4 for analysis based on the Shannon Index.
|
Day 4
|
|
Microbial Community Diversity - Day 5
Time Frame: Day 5
|
Swabs will be collected on the back at Day 5 for analysis based on the Shannon Index.
|
Day 5
|
|
Microbial Community Diversity - Day 6
Time Frame: Day 6
|
Swabs will be collected on the back at Day 6 for analysis based on the Shannon Index.
|
Day 6
|
|
Microbial Community Diversity - Day 7
Time Frame: Day 7
|
Swabs will be collected on the back at Day 7 for analysis based on the Shannon Index.
|
Day 7
|
|
Microbial Community Diversity - Day 14
Time Frame: Day 14
|
Swabs will be collected on the back at Day 14 for analysis based on the Shannon Index.
|
Day 14
|
|
Microbial Community Evenness - Baseline (Day 0)
Time Frame: Day 0
|
Swabs will be collected on the back at Baseline (Day 0) for analysis based on the Pielou's Evenness Index.
|
Day 0
|
|
Microbial Community Evenness - Day 1
Time Frame: Day 1
|
Swabs will be collected on the back at Day 1 for analysis based on the Pielou's Evenness Index.
|
Day 1
|
|
Microbial Community Evenness - Day 2
Time Frame: Day 2
|
Swabs will be collected on the back at Day 2 for analysis based on the Pielou's Evenness Index.
|
Day 2
|
|
Microbial Community Evenness - Day 3
Time Frame: Day 3
|
Swabs will be collected on the back at Day 3 for analysis based on the Pielou's Evenness Index.
|
Day 3
|
|
Microbial Community Evenness - Day 4
Time Frame: Day 4
|
Swabs will be collected on the back at Day 4 for analysis based on the Pielou's Evenness Index.
|
Day 4
|
|
Microbial Community Evenness - Day 5
Time Frame: Day 5
|
Swabs will be collected on the back at Day 5 for analysis based on the Pielou's Evenness Index.
|
Day 5
|
|
Microbial Community Evenness - Day 6
Time Frame: Day 6
|
Swabs will be collected on the back at Day 6 for analysis based on the Pielou's Evenness Index.
|
Day 6
|
|
Microbial Community Evenness - Day 7
Time Frame: Day 7
|
Swabs will be collected on the back at Day 7 for analysis based on the Pielou's Evenness Index.
|
Day 7
|
|
Microbial Community Evenness - Day 14
Time Frame: Day 14
|
Swabs will be collected on the back at Day 14 for analysis based on the Pielou's Evenness Index.
|
Day 14
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Barrier Function -Baseline (Day 0)
Time Frame: Day 0
|
The skin barrier function of the test sites will be evaluated at Baseline (Day 0) by Trans Epidermal Water Loss (TEWL).
|
Day 0
|
|
Skin Barrier Function - Day 1
Time Frame: Day 1
|
The skin barrier function of the test sites will be evaluated at Day 1 by Trans Epidermal Water Loss (TEWL).
|
Day 1
|
|
Skin Barrier Function - Day 2
Time Frame: Day 2
|
The skin barrier function of the test sites will be evaluated at Day 2 by Trans Epidermal Water Loss (TEWL).
|
Day 2
|
|
Skin Barrier Function - Day 3
Time Frame: Day 3
|
The skin barrier function of the test sites will be evaluated at Day 3 by Trans Epidermal Water Loss (TEWL).
|
Day 3
|
|
Skin Barrier Function - Day 4
Time Frame: Day 4
|
The skin barrier function of the test sites will be evaluated at Day 4 by Trans Epidermal Water Loss (TEWL).
|
Day 4
|
|
Skin Barrier Function - Day 5
Time Frame: Day 5
|
The skin barrier function of the test sites will be evaluated at Day 5 by Trans Epidermal Water Loss (TEWL).
|
Day 5
|
|
Skin Barrier Function - Day 6
Time Frame: Day 6
|
The skin barrier function of the test sites will be evaluated at Day 6 by Trans Epidermal Water Loss (TEWL).
|
Day 6
|
|
Skin Barrier Function - Day 7
Time Frame: Day 7
|
The skin barrier function of the test sites will be evaluated at Day 7 by Trans Epidermal Water Loss (TEWL).
|
Day 7
|
|
Skin Barrier Function - Day 14
Time Frame: Day 14
|
The skin barrier function of the test sites will be evaluated at Day 14 by Trans Epidermal Water Loss (TEWL).
|
Day 14
|
|
Redness: Wound Area Oxyhemoglobin Level- Baseline (Day 0)
Time Frame: Day 0
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 0
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 1
Time Frame: Day 1
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 1
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 2
Time Frame: Day 2
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 2
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 3
Time Frame: Day 3
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 3
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 4
Time Frame: Day 4
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 4
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 5
Time Frame: Day 5
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 5
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 6
Time Frame: Day 6
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 6
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 7
Time Frame: Day 7
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 7
|
|
Redness: Wound Area Oxyhemoglobin Level - Day 14
Time Frame: Day 14
|
Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site.
Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm.
The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.
|
Day 14
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Philip Lastella, MD, TKL Research, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CO-170726100607-SACT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
NCT01739647CompletedHealthy Elderly Volunteers | Healthy Young Volunteers
-
NCT02922933CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT02922946CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT04753580CompletedHealthy Volunteers | Frail Volunteers
-
NCT03769389CompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy Volunteers
-
NCT03194139Completed
-
NCT03164109Completed
-
NCT03163173CompletedHealthy | Healthy Volunteers
-
NCT06646458CompletedHealthy Elderly | Healthy Volunteers
-
NCT06671301CompletedHealthy Adults | Healthy Volunteers Only
Clinical Trials on ADHESIVE BANDAGE #1
-
NCT04040933Completed
-
NCT04888520Not yet recruiting
-
NCT07066254Not yet recruitingSurgical Site Infection Following Cesarean Delivery
-
NCT00816101Completed
-
NCT05173974Completed
-
NCT07496164Recruiting